1. Home
  2. Calendar of Events
  3. Webinars
  4. Previous Webinars
  5. What is the Preferred Marker of Cardiac Myocyte Injury or Death in 2021?

What is the Preferred Marker of Cardiac Myocyte Injury or Death in 2021?

Aug 5, 2021

Description 

Ischemic heart disease (IHD) is the number one cause of death, disability, and human suffering globally. It is estimated that IHD affects around 126 million individuals globally, and the prevalence of IHD is rising.1 Our live webinar will help laboratories in their efforts to address IHD. Join William Winter, MD, FCAP in this 60-minute session as he focuses on this highly anticipated clinical chemistry topic. He will educate on myocardial injuries, cardiac markers, and their differences. The session includes time at the end to answer submitted questions.

1. Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. Published 2020 Jul 23. doi:10.7759/cureus.9349

Learning Objectives

  • Define and differentiate myocardial injury, acute myocardial injury, and myocardial infarction
  • List the five subtypes of myocardial infarction
  • Identify atherothrombosis as the most common cause of myocardial infarction
  • Choose the best plasma marker for the detection of cardiac myocyte injury and necrosis
  • Explain to laboratorians and clinicians the superiority of high sensitivity troponin measurements over traditional troponin measurements

Presenter

Dr. William Winter, MD, FCAP

  • Awarded Professor of Pathology and Pediatrics at the University of Florida in Gainesville, Florida; teaching Foundations of Medicine, Microbiology and Immunology Fundamentals, Pain Management and Endocrinology.
  • Board Certifications in pediatrics, pediatric endocrinology, and chemical pathology
  • Fellow of College of American Pathologists (CAP) and member of CAP Clinical Pathology Education Committee, fellow of American Association for Clinical Chemistry Academy (FAACC), and diplomate of the American Board of Clinical Chemistry (ABCC)
  • NIH-funded principle investigator the Type 1 Diabetes TrialNet Islet Cell Autoantibody Core Laboratory, TEDDY Core Laboratory, and the RADIANT Central Laboratory

Webinar Materials

Handout (PDF)

Watch recording

To Top